412 related articles for article (PubMed ID: 25121186)
21. Consensus Statement of HCV Task Force of the Indian National Association for Study of the Liver (INASL). Part II: INASL Recommendations for Management of HCV in India.
Puri P; Anand AC; Saraswat VA; Acharya SK; Sarin SK; Dhiman RK; Aggarwal R; Singh SP; Amarapurkar D; Arora A; Chhabra M; Chetri K; Choudhuri G; Dixit VK; Duseja A; Jain AK; Kapoor D; Kar P; Koshy A; Kumar A; Madan K; Misra SP; Prasad MV; Nagral A; Puri AS; Jeyamani R; Saigal S; Shah S; Sharma PK; Sood A; Thareja S; Wadhawan M
J Clin Exp Hepatol; 2014 Jun; 4(2):117-40. PubMed ID: 25755549
[TBL] [Abstract][Full Text] [Related]
22. Factors influencing the response to interferon therapy in chronic hepatitis C. Studies on viral genotype and induction of 2',5'-oligoadenylate synthetase in the liver and peripheral blood cells.
Grandér D; Hultcrantz R; Weiland O; Xu B; Sangfelt O; Björklund AC; Befrits R; Björkholm M; Gruber A; Kinnman N; Reichard O; Widell A; Einhorn S
Scand J Gastroenterol; 1996 Jun; 31(6):604-11. PubMed ID: 8789901
[TBL] [Abstract][Full Text] [Related]
23. Selection of more pathogenic hepatitis C virus genotype II during long-term follow-up of interferon-treated patients.
Villa E; Buttafoco P; Merighi A; Grottola A; Ferretti I; Ferrari A; Callea F; Trande P; Rebecchi AM; Manenti F
J Mol Med (Berl); 1995 May; 73(5):249-54. PubMed ID: 7545526
[TBL] [Abstract][Full Text] [Related]
24. Management of viral hepatitis C.
Leung NW
J Gastroenterol Hepatol; 2002 Feb; 17 Suppl():S146-54. PubMed ID: 12000600
[TBL] [Abstract][Full Text] [Related]
25. Serological and salivary markers compared with biochemical markers for monitoring interferon treatment for hepatitis C virus infection.
Roy KM; Bagg J; Bird GL; Spence E; Follett EA; Mills PR; Lau JY
J Med Virol; 1995 Dec; 47(4):429-34. PubMed ID: 8636714
[TBL] [Abstract][Full Text] [Related]
26. Predictors of a favorable response to alpha interferon therapy for hepatitis C.
Barnes E; Webster G; Whalley S; Dusheiko G
Clin Liver Dis; 1999 Nov; 3(4):775-91. PubMed ID: 11291250
[TBL] [Abstract][Full Text] [Related]
27. [Management of patients infected with hepatitis C virus].
Sobesky R; Buffet C
Presse Med; 2001 Apr; 30(14):667-72. PubMed ID: 11360728
[TBL] [Abstract][Full Text] [Related]
28. New advances in hepatitis C therapy.
Proj Inf Perspect; 2000 Aug; (30):18-9. PubMed ID: 12171011
[TBL] [Abstract][Full Text] [Related]
29. Interferon therapy in chronic hepatitis C virus infection.
Weiland O
FEMS Microbiol Rev; 1994 Jul; 14(3):279-88. PubMed ID: 8086199
[TBL] [Abstract][Full Text] [Related]
30. Long-term follow up of chronic hepatitis C patients after alpha-interferon treatment: a functional study.
Giannini E; Fasoli A; Botta F; Testa E; Romagnoli P; Ceppa P; Testa R
J Gastroenterol Hepatol; 2001 Apr; 16(4):399-405. PubMed ID: 11354278
[TBL] [Abstract][Full Text] [Related]
31. HCV genotypes--role in pathogenesis of disease and response to therapy.
Webster G; Barnes E; Brown D; Dusheiko G
Baillieres Best Pract Res Clin Gastroenterol; 2000 Apr; 14(2):229-40. PubMed ID: 10890318
[TBL] [Abstract][Full Text] [Related]
32. New approaches in the treatment of hepatitis C.
González-Grande R; Jiménez-Pérez M; González Arjona C; Mostazo Torres J
World J Gastroenterol; 2016 Jan; 22(4):1421-32. PubMed ID: 26819511
[TBL] [Abstract][Full Text] [Related]
33. Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection in 2015.
Puri P; Anand AC; Saraswat VA; Acharya SK; Dhiman RK; Sarin SK; Singh SP; Chawla YK; Aggarwal R; Amarapurkar D; Arora A; Dixit VK; Sood A; Shah S; Duseja A; Kapoor D; Shalimar ; Madan K; Pande G; Nagral A; Kar P; Koshy A; Puri AS; Eapen CE; Thareja S
J Clin Exp Hepatol; 2015 Sep; 5(3):221-38. PubMed ID: 26628840
[TBL] [Abstract][Full Text] [Related]
34. Treatment strategies for chronic hepatitis C: update since the 1997 National Institutes of Health Consensus Development Conference.
Ahmed A; Keeffe EB
J Gastroenterol Hepatol; 1999 May; 14 Suppl():S12-8. PubMed ID: 10382632
[TBL] [Abstract][Full Text] [Related]
35. [Induction therapy with interferon alfa-2a in compensated hepatitis C virus-related cirrhosis. Randomized, multicenter study].
Planas R; Quer JC; Enríquez J; Barrera JM; Dalmau B; Casanovas T; Viver JM; Torres M; Boadas J; Solà R; Durández R; Richart C; Bruguera M
Med Clin (Barc); 2002 May; 118(17):641-4. PubMed ID: 12028899
[TBL] [Abstract][Full Text] [Related]
36. Hepatitis C virus genotypes in patients with chronic liver disease and haemodialysis patients from Saudi Arabia.
al-Faleh FZ; Huraib S; Sbeih F; al-Karawi M; al-Rashed R; al-Mofleh IA; Sougiyyah M; Shaheen M; Ramia S
J Viral Hepat; 1995; 2(6):293-6. PubMed ID: 8732175
[TBL] [Abstract][Full Text] [Related]
37. Clinical significance of hepatitis C virus genotypes.
Mondelli MU; Silini E
J Hepatol; 1999; 31 Suppl 1():65-70. PubMed ID: 10622563
[TBL] [Abstract][Full Text] [Related]
38. Hepatitis C virus genotypes: distribution and clinical significance in patients with cirrhosis type C seen at tertiary referral centres in Europe.
Fattovich G; Ribero ML; Pantalena M; Diodati G; Almasio P; Nevens F; Tremolada F; Degos F; Rai J; Solinas A; Mura D; Tocco A; Zagni I; Fabris F; Lomonaco L; Noventa F; Realdi G; Schalm SW; Tagger A;
J Viral Hepat; 2001 May; 8(3):206-16. PubMed ID: 11380799
[TBL] [Abstract][Full Text] [Related]
39. Therapeutic advances in the management of hepatitis B and hepatitis C.
Nguyen MH; Wright TL
Curr Opin Infect Dis; 2001 Oct; 14(5):593-601. PubMed ID: 11964881
[TBL] [Abstract][Full Text] [Related]
40. [Characteristics of the hepatitis C virus and viral predictors of therapeutic response].
Ambrosch A; König W
Med Klin (Munich); 1999 Nov; 94(11):626-32. PubMed ID: 10603734
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
